期刊文献+

心血管内科非瓣膜性心房颤动住院患者的抗凝治疗效果分析

下载PDF
导出
摘要 目的分析医院心血管内科非瓣膜性心房颤动住院患者的抗凝治疗效果。方法选取医院2015年6月-2018年6月收治的心血管内科非瓣膜性心房颤动住院患者200例进行回顾性分析,总结患者抗凝治疗情况。结果心血管内科非瓣膜性心房颤动住院患者以老年人群为主,伴发基础疾病包括高血压、糖尿病、冠心病、心力衰竭、血管疾病、脑卒中史及出血史;接受单药抗凝治疗40例(20.00%),仅接受抗血小板治疗100例(50.00%),接受联合抗栓治疗50例(25.00%),未接受抗凝治疗10例(5.00%)。75例接受华法林抗凝治疗的患者中INR达标的有8例。CHA2SD2-VASc评分为0分的患者抗凝治疗率为12.50%,评分为1分的患者抗凝治疗率为10.00%,评分≥2分的患者抗凝治疗率为77.50%;出血HAS-BLED评分<3分的患者抗凝治疗率为95.00%,评分≥3分的患者抗凝治疗率为5.00%。血栓4例,其中1例为接受华法林抗凝治疗的患者;出血患者3例,其中1例为接受华法林抗凝治疗的患者。结论抗凝是治疗心血管内科非瓣膜性心房颤动患者的重要方法,但临床抗凝治疗实施率处于较低水平,新型口服抗凝药物在临床应用较少。
作者 龙文
出处 《临床合理用药杂志》 2019年第34期55-56,共2页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献12

二级参考文献126

  • 1左惠娟,苏江莲,曾辉,袁宝弘,姚崇华.北京市非瓣膜心房颤动病人日常抗血栓治疗现况分析[J].中华医学杂志,2007,87(33):2328-2331. 被引量:18
  • 2Salem DN, Stein PD, Al-Ahmad A, et al. Antithrombotic therapy in valvular heart disease-native and prosthetic:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[J]. Chest J, 2004, 126(Suppl 3):457S-482S.
  • 3Cai H, Li Z, Goette A. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation potential mechanisms for atrial thrombosis and stroke[J]. Circulation, 2002, 106(22):2854-2858.
  • 4Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation[J]. Circulation, 1997, 96(4):1180-1184.
  • 5Boldt A, Wetzel U, Lauschke J, et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease[J]. Heart, 2004, 90(4):400-405.
  • 6Lip GYH, Rumley A, Dunn FG, et al. Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation:effects of cardioversion to sinus rhythm[J]. Int J Cardiol, 1995:51(3):245-251.
  • 7Christersson C, Johnell M, Siegbahn A, et al. The influence of direct thrombin inhibitors on the formation of platelet-leukocyte aggregates and tissue factor expression[J]. Thromb Res, 2010, 126(4):e327-e333.
  • 8Chung NAY, Belgore F, Li-Saw-Hee FL, et al. Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth factor?[J]. Stroke, 2002, 33(9):2187-2191.
  • 9Furie B, Furie BC, Flaumenhaft R, et al. A journey with platelet P-selectin:the molecular basis of granule secretion, signalling and cell adhesion[J]. Thromb Haemost, 2001, 86(1):214-221.
  • 10Tsutsumi Y, Shimono J, Ohhigashi H, et al. Analysis of the influence of dabigatran on coagulation factors and inhibitors[J]. Int J Lab Hematol, 2015, 37(2):225-230.

共引文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部